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Although cellular and molecular bases of proliferative diabetic retinopathy are only partially understood, it is evident that this
complication of diabetes is characterized by the formation of new vessels inside the retina showing abnormal architecture and
permeability. This process, if not controlled by selective laser photocoagulation, leads to irreversible retinal damages and loss of
vision. Angiogenesis, that is, the condition characterized by the growth of new blood vessels originated from preexisting ones,
was shown to have a major role in the pathogenesis of proliferative retinopathy and, as a consequence, intravitreal antiangiogenic
injection was suggested as a feasible treatment for this disease. Here, we describe the diﬀerent antiangiogenic approaches used
to treat this disease along with the respective advantages and limitations when compared to laser treatment. Altogether, even
though further and longer studies are still needed to clarify the best possible therapeutic protocol, the antiangiogenic treatment
will reasonably have a future role in the therapy and prevention of proliferative diabetic retinopathy.
1.Introduction
As a consequence of the ongoing worldwide epidemic of
type 2 diabetes [1], we expect that in few years a similar
outbreak of diabetic complications, and in particular of
diabetic retinopathy, will eventually follow [2, 3]. Among the
complicationsofdiabeticretinopathy,whichcarryanimpor-
tant vision impairment, there are diabetic macular edema
and proliferative diabetic retinopathy. More recent data
comes from study conducted in USA in which investigators
estimated that the prevalence of diabetic retinopathy was
28.5%, among persons with diabetes aged 40 years and older.
Approximately,1.5%ofadultswithdiabeteshadproliferative
diabetic retinopathy and 2.7% had clinically signiﬁcant mac-
ular edema [4].
In particular, the proliferative stage is characterized by
the formation of new leaky vessels spreading without regular
orientationontheretinalsurface,ofteninvadingthevitreous
cavity, and ﬁnally leading to hemorrhage, ﬁbrosis, and trac-
tional retinal detachment.
Despite the evidence that the prevalence of proliferative
diabetic retinopathy (PDR) is progressively decreasing as a
consequence of the improved techniques aimed to control
glucose metabolism [4–7], the overall situation is worsening
once again as a consequence of the increased prevalence of
type2diabetes.AtriplicationofnewcasesofPDRisforeseen
in the next forty years [2].
2. Angiogenesis
Angiogenesis is the physiologic condition characterized by
the growth of new blood vessels originated from preexisting
ones.2 Experimental Diabetes Research
The angiogenic process follows several steps: ﬁrst of all, a
number of angiogenic growth factors activate the receptors
present on resident endothelial cells. Once activated, the
endothelial cells begin to release speciﬁc enzymes called pro-
teases that degrade the basement membrane, ﬁnally allowing
endothelialcellstoleavetheoriginal(parental)vesselwall.At
this stage, endothelial cells proliferate into the surrounding
matrix, taking advantage of adhesion molecules called in-
tegrins.Angiogenesismayrepresentapharmacologicaltarget
for combating diseases characterized by either poor vascu-
larization or hypertrophic vasculature. Antiangiogenic ther-
apies, in particular, are presently employed to ﬁght cancer
and other malignancies.
Concerning the eye, the angiogenic process has to be
considered as a pathologic phenomenon. There are actually
several conditions leading to the formation of abnormal
neovascularization. Age-related macular degeneration is one
of the most important diseases characterized by the forma-
tion of choroidal new vessel in the macular region ﬁnally
leading; if untreated, to vision loss. The other major disease
characterized by abnormal formation of retinal vessels is
diabetic retinopathy, in particular the so-called proliferative
stage of this disease. Regarding both retina and choroid,
vascularendothelialgrowthfactor(VEGF)wasshowntobea
major contributor to angiogenesis by increasing the number
of new capillaries.
VEGF concentration levels, in particular, were found to
be signiﬁcantly increased in ocular tissues from patients with
diabetes [8]. This ﬁnding raised the question of the potential
role of VEGF in the pathogenesis of DR.
3. Role of Angiogenesis in
the Pathogenesis of PDR
A number of evidences suggest that VEGF, and consequently
angiogenesis, is involved in the pathogenesis of PDR [9]. The
ﬁnding that most of VEGF production in solid tumors is
due to hypoxia stimulus [10] suggested that VEGF might be
an ideal candidate to mediate the hypoxia-induced intraoc-
ular neovascular response. Furthermore, VEGF is both an
endothelial speciﬁc mitogen and vascular permeability fac-
tor. This ﬁnding suggests that VEGF could account for both
proliferation and vasopermeability in course of proliferative
diabetic retinopathy [11].
In humans, diabetic patients with established PDR have
indeed high levels of VEGF in the vitreous and this dysfunc-
tion can be normalized only by laser photocoagulation [12].
Accordingly, in mouse models of ischemic retinopathy, it is
also possible to prevent the development of the proliferative
stage by blocking VEGF activity [13]. Finally, intravitreal
injectionofVEGFwasshowntocauseirisneovascularization
in primates [14].
From a functional point of view, VEGF has been identi-
ﬁed as a proinﬂammatory mediator, reasonably involved in
the development of the inﬂammatory process that accom-
panies the progression of DR. VEGF actually increases the
expression of the cellular adhesion molecule ICAM-1 a
chemotactic factor for monocyte/macrophage lineage cells
[15, 16]. Through the activation of ICAM-1, VEGF, there-
fore, promotes leukostasis (and vascular leakage) and in-
creases leukocyte counts in the retinas of diabetic animals
[17, 18] and in human diabetic retinas [19]C o n v e r s e l y ,
blockage of VEGF decreases retinal leukocyte counts in
experimental diabetes [20]. Altogether these ﬁndings pro-
vided a robust rationale for the setting up of clinical trials
to verify VEGF blockade as a therapy for DR.
4.IntravitrealAnti-VEGFTreatmentas
a Therapy for PDR: Comparison with
LaserTreatment
Panretinal photocoagulation (PRP) is at present the only
successfulevidence-basedtreatmentforPDR.PRPreducesin
fact the risk of severe visual loss by 50–60% with regression
of the majority of neovascularizations over a period of 3
months. In particular, it was shown that when PDR regresses
within the ﬁrst 3 months after PRP treatment, the visual
prognosis tends to be excellent [21].
Among the proposed mechanisms underlying PRP eﬀec-
tiveness are reduced oxygen requirement that follows the
destruction of the highly metabolically active outer reti-
nal cells and improved retinal oxygenation derived from
choroidal circulation. Several attempts have been made to
modify PRP laser techniques to reduce side-eﬀects such as
decreased visual acuity, peripheral ﬁeld loss, and macular
edema [22]. Despite this evidence, several patients still
require supplemental laser treatment, and nearly 4.5% show
disease progression that ﬁnally require pars plana vitrectomy
(PPV), even in presence of an adequate PRP [23].
Limits of PRP include poor response to treatment, pain,
nyctalopia, loss of peripheral vision, uveal eﬀusions, worsen-
ing of macular edema, and diﬃculty to treat eyes with vitre-
ous hemorrhage.
Most patients require at least two treatment sessions and
several return for multiple additional sessions in case of per-
sistent neovascularisation.
Altogether, nondestructive approaches alternative to
PRP, such as VEGF inhibition, have been recently investi-
gated as possible new therapies for PDR [24].
ThemoleculescurrentlyunderinvestigationtotreatPDR
are Macugen (Pegaptanib sodium), Lucentis (Ranibizumab),
and Avastin (Bevacizumab). The widespread use of these
molecules in clinical practice is so far limited by their short-
lived eﬀects and the lack of established protocols.
4.1. Macugen. Pegaptanib sodium (Macugen, Eyetech Inc,
Cedar Knolls, NJ, USA) is a 28-nucleotide RNA aptamer
that binds speciﬁcally to the VEGF-A165 isomer, the major
pathological VEGF protein in the eye.
4.2. Lucentis. Ranibizumab (Lucentis; Genentech USA,
Inc., San Francisco, CA, USA/Novartis ophthalmics, Basel,
Switzerland) is an engineered, humanized, recombinant
antibody fragment (Fab) active against all VEGF-A isoforms.
As it lacks the Fc domain, it has a much shorter half-life
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as an intravitreal agent for the treatment of wet, age-related,
macular degeneration (ARMD).
4.3. Avastin. Bevacizumab (Avastin; Genentech Inc., San
Francisco, CA, USA) is a full-lengthrecombinant humanized
antibody active against all isoforms of VEGF-A. This large
sized molecule (molecular weight: 148kDa) has two times
the half-life of ranibizumab, with a prolonged eﬀect on
retinal neovascularisation [25].
Bevacizumab is currently not licensed for intraocular
use but is nonetheless the most used among anti-VEGF
agents. Three randomized nonplacebo controlled trials on
intravitreal bevacizumab for the treatment of PDR have been
recently published [26–28]. Several other clinical trials are
presently ongoing (http://www.clinicaltrials.org).
The standard average endpoint for evaluating the eﬀec-
tiveness of anti-VEGF treatments is commonly considered as
the persistence of the eﬀect of treatment for at least 6 months
after the intraocular injection. Unfortunately, few clinical
studies include a 6-month followup. Comparative analysis
between diﬀerent studies is not so simple as quantitative
evaluation of the extent and severity of neovascularization
diﬀer between individuals. And this makes more diﬃcult the
translation of results of these studies into clinical practice.
In a retrospective analysis, Adamis et al. [29]d e m o n -
strated a persistent beneﬁcial eﬀectof intravitreal pegaptanib
in patients with PDR, with 62% of the treated eyes showing
regression or absence of neovascularization 6 months after
injection.
Ar e c e n ts t u d yf r o mC h oe ta l .[ 30] studied the eﬀects
of intravitreal injection of Bevacizumab on VEGF expression
and inﬂammation in ﬁbrovascular membranes from 18
patients with PDR. An immunohistochemical staining for
VEGF, CD31, and CD68 was performed in three diﬀerent
groups; group 1:4 inactive PDR eyes, group 2:10 active
PDR eyes treated preoperatively with adjunctive intravit-
real bevacizumab, group 3:5 active PDR eyes not treated
preoperatively with bevacizumab. They found that IVB
caused some reduction in VEGF expression and vascular
densities in a limited number of active PDR patients, but
they also demonstrated that a single injection may not be
enoughtoinducecompleteblockageofVEGFandpathologic
neovascularization in active PDR patients.
A possible solution to overcome these limits in eﬃcacy
could result from combined therapy consisting in laser
treatment followed by intravitreal injection of anti-VEGF.
This approach could have some advantage by increasing
the extent of treatment, by accelerating the eﬀect of laser
photocoagulation, and by providing alternative therapeutic
solutions when laser delivery by itself is diﬃcult or impossi-
ble.
5.Bevacizumab
Concerning Bevacizumab and laser treatment, the study
donebyMirshahietal.[31]isprobablythelargestperformed
to date. Forty patients with type 2 diabetes and PDR in both
eyes with high risk proﬁle underwent scatter laser treatment
following the ETDRS protocol and had a single bevacizumab
injection in one eye; sham injection was performed in the
controlateral eye used as control. This study demonstrated
t h a ta tw e e ks i x8 7 . 5 %o fe y e st r e a t e dw i t hb e v a c i z u m a bh a d
complete regression of neovascularization versus 25% in the
sham treated group (P<0.005). At week 16, the diﬀerence
between the two groups disappeared. This study provides
further evidence that bevacizumab has an inhibitory eﬀect
on the formation of new vessels. This study allows to con-
clude that intravitreal bevacizumab is a valid treatment for
early high-risk PDR.
5.1. Eyes Resistant to Panretinal Photocoagulation (PRP). The
eﬀect of intravitreal Bevacizumab in eyes with persistent,
active PDR was assessed by Jorge and colleagues in a
noncomparative trial [32]. One injection of bevacizumab
was administered to 15 eyes that were then followed for 12
weeks. As a result, best-corrected visual acuity (BCVA) was
improved signiﬁcantly from baseline at all time points (1,
6, and 12 weeks), from 20/160 at baseline to approximately
20/125 at 12 weeks. The mean area of ﬂuorescein leakage was
also improved signiﬁcantly at all time points. No signiﬁcant
adverse events could be demonstrated. If these results will
be conﬁrmed by further and larger studies, bevacizumab
will be identiﬁed as an important intervention for eyes with
refractory PDR.
Intravitreal bevacizumab for cases that were not respon-
sive to traditional PRP has been evaluated in another study
by Moradian and colleagues [33]. Thirty eight eyes received
a bevacizumab injection at baseline, and after 6 or 12 weeks
according to the research protocol. Clearance of vitreous
hemorrhageandregressionofactiveﬁbrovasculartissuewere
considered as endpoints. A tendency toward resolution of
vitreous hemorrhage with a trend toward signiﬁcance could
be shown at 6 weeks (P = 0.06). No signiﬁcant change
in the extent of ﬁbrovascular tissue occurred, even though
several eyes could not be evaluated for this variable because
of media opacity. The most remarkable ﬁnding in this
study was probably the occurrence of two tractional retinal
detachments (5.3% of study eyes). This ﬁnding is in line
with the report by Arevalo and colleagues that 5.2% of the
eyes with PDR developed TRD after an extra intravitreal
bevacizumab injection performed before vitrectomy [34].
Taken together, the above-described studies suggest that
intravitreal bevacizumab decreases leakage from diabetic
neovascular lesions in newly diagnosed and refractory dis-
ease. Further studies are now necessary, particularly on pos-
sible long-time side eﬀects before we will be able to translate
these research ﬁndings into clinical practice.
5.2.In Caseof VitreousHemorrhage. Persistentandrecurrent
vitreous hemorrhage is a common complication of vitrec-
tomy for diabetic retinopathy with an incidence ranging
from 12% to 63% [35].
Bevacizumab was shown to reduce intra- and postopera-
tive bleeding and surgical operating times when used before
the surgical removal of vitreomacular membranes [36–38]
In most studies, bevacizumab has been administered for just4 Experimental Diabetes Research
oneweekpreoperatively,toavoidtheoccurrenceoftractional
retinal detachment in patients with severe PDR [33, 34].
In a study, Rizzo and colleagues randomized 22 eyes with
severe PDR and TRD either to intravitreal bevacizumab 5
to 7 days before PPV or to placebo [28]. As a result, they
demonstrated that diﬃculties in the surgical procedure, as
evaluated by recording operative times, number of instru-
ment exchanges, number and severity of intraoperative
bleeds, dissection techniques, and intraoperative retinal tears
were reduced in the bevacizumab group.
Similarly, Yeh and colleagues tested the eﬀect of beva-
c i z u m a ba sa na d j u v a n tt h e r a p y1w e e kb e f o r ev i t r e c t o m y
[37]. They enrolled 41 eyes with severe PDR and active
ﬁbrovascular proliferation extended to the periphery. The
authorsrandomizedtheseeyestobevacizumabortoplacebo.
As a result, intraoperative bleeding from proliferative tissue
was signiﬁcantly worse in the control group, even though
intraoperative subretinal hemorrhage was more frequent in
the bevacizumab group (P = 0.004). The authors concluded
that although an increased rate of intraoperative subretinal
hemorrhage occurred in the bevacizumab group, several
potentialbeneﬁtsofthedrugﬁnallyoutweighedtheobserved
adverse eﬀects.
A large trial of bevacizumab along with vitrectomy has
been recently performed by Ahmadieh and colleagues [38].
The authors randomized 68 eyes scheduled to undergo PPV
for PDR to intravitreal bevacizumab, 1 week before PPV, or
to sham injection. Only 34 eyes completed the study as in
severalcasestreatedwithbevacizumabasigniﬁcantimprove-
ment during the week after the injection could be demon-
strated. The incidence of postvitrectomy haemorrhage 1
week and at 1 month after surgery was signiﬁcantly lower in
the group treated with bevacizumab compared to the con-
trols (P = 0.023 and P = 0.001, resp.). Also intraoperative
bleeding was signiﬁcantly less in the bevacizumab group
(P = 0.035), as was the need to use intraoperative endo-
diathermy.
Altogether, the above-described studies indicate that
bevacizumab before vitrectomy represent a valid approach
for PDR. Injection of bevacizumab 1 or 2 weeks before PPV
did not cause any adverse outcomes. Further studies with
a larger number of patients are now warranted to conﬁrm
these preliminary results.
5.3. In Case of Neovascular Glaucoma. Anti-VEGF agents
might have role in the management of one of the most severe
forms of secondary glaucoma, the so-called neovascular
glaucoma (NVG).
On this regard, Chalam et al. [39] reported complete
regression of neovascularization due to aggressive NVG
within 3 weeks from the treatment with bevacizumab.
A trial on 26 eyes with NVG was performed by Costagli-
ola et al. [40]. The authors demonstrated that at the end of
the treatment, in all patients, it was possible to appreciate
a regression of neovascularisation paralleled by a reduction
of intraocular pressure (IOP). After one year of followup,
however, three eyes required glaucoma valve implants and 14
patients were treated with standard glaucoma medication.
A massive regression of iris neovascularization in a 2-
week period and no signiﬁcant changes in IOP could be
demonstrated in NVG patients treated with injection of
bevacizumab by Lim et al. [41].
Finally, Eid et al. [42] recently demonstrated that com-
bining bevacizumab with good PRP ablated the ischaemic
retina and ensured good success rates in 20 patients with
intractable glaucoma.
5.4. In Case of Chataract Surgery. S i x t y - e i g h te y e sw i t ha n y
type of DR at the end of cataract surgery were randomized
to bevacizumab by Cheema and colleagues [43]. As a result,
1 month after treatment, 5 control eyes progressed in the
severity of DR versus only four treated eyes (P = 0.002).
Macular edema was also more common in control eyes.
Takamura and colleagues also injected bevacizumab at
the conclusion of cataract surgery in diabetic patients [44].
During the followup the treated eyes, when compared to
control eyes had a signiﬁcant improvement with respect to
preoperative measurements.
A similar study was performed by Lanzagorta-Aresti and
colleagues [45] in patients with moderate NPDR and DME.
Twenty-six eyes that underwent laser treatment followed
by uncomplicated cataract surgery received bevacizumab or
sham injection. As a result, the treated group showed a
signiﬁcant improvement in BCVA and no change in CMT.
The sham group showed a worsening of visual acuity and
a signiﬁcant increase in CMT. Although the results look
promising, further studies are now necessary to conﬁrm
these early ﬁndings.
6.PegaptanibSodium
The eﬀect of intravitreal Pegaptanib (Macugen) on diabetic
macular edema [46] was evaluated in retrospective analysis
aimed to compare the eﬀect of pegaptanib on ocular neovas-
cularization to a sham group. Sixteen subjects were included
in the study. Eight subjects in the intravitreal pegaptanib
group (n = 13) showed regression of neovascularization
(62%) at 36 weeks, whereas none of the eyes in sham
group (n = 3) showed regression of neovascularization.
However, in three of the eight treated eyes (37.5%), ocular
neovascularisation recurred at the end of followup.
More recently, Gonz´ alez et al. [47] performed a prospec-
tive, randomized, controlled, open label study aimed to
clarify the eﬃcacy of intravitreal pegaptanib versus PRP in
the treatment of active PDR. As a result, by week 12, in all
eyes receiving pegapanib, a complete regression of retinal
proliferation could be demonstrated and was maintained
through week 36.
7.Ranibizumab
There are no ﬁnal reports on the eﬀect of ranibizumab
on PDR [48]. The Diabetic Retinopathy Clinical Research
Network (DRCRnet) is presently performing a randomized
prospectivecontrolledtrialtodeterminewhetherintravitreal
ranibizumab or a steroid given to patients with PDR andExperimental Diabetes Research 5
macular edema can reduce the risk of visual loss following
PRP and provide good visual outcomes over a short term.
The primary outcome measure includes visual acuity out-
comes at 14 weeks. Secondary outcome measures include
changes in retinal thickness, presence, and extent of new
vessels on fundus photos and vitreous haemorrhage.
The study is currently closed and the scientiﬁc commu-
nity is waiting for the ﬁnal results. (Intravitreal Ranibizumab
orTriamcinolone AcetonideasAdjunctiveTreatmenttoPan-
retinal PhotocoagulationforProliferativeDiabetic Retinopa-
thy. Available at: http://drcrnet.jaeb.org/ Accessed: May 10,
2011).
8. Other Anti-VEGFDrugs
Among the others, a new and alternative way to block VEGF
is represented by VEGF-trap (aﬂibercept). VEGF-trap is a
fusion protein made of immunoglobulin domains of both
VEGF-1 and -2 fused to an Fc-fragment of human IgG.
VEGF -trapactsasasol ubler ec ept orasitisablet obindev ery
isoformofextracellularVEGF[49].Whetherthisapproachis
really eﬀective and may reduce the side eﬀects of standard
anti-VEGF therapy remains to be seen. A major problem
with pan-isoform blockade of VEGF is indeed the decrease
in physiologic revascularization, a process that is important
in preventing PDR [50].
RNA interference is a classic example of basic research
that has moved from bench to bedside. Intracellular tran-
scription of VEGF can actually be shut down by means
of RNA interference, ﬁnally decreasing the production of
VEGF released from the retinal pigment epithelium. This
kind of approach is presently studied in treatment of wet
AMD [51]. As previously done with other anti-VEGF drugs,
after demonstration of its safety and eﬃcacy in neovascular
AMD, RNA interference will for sure explore also patients
with PDR.
Finally, another novel therapy may consist in the use of
small molecules that, acting as tyrosine kinase inhibitors,
become able to inhibit the intracellular signaling cascade of
VEGF. These substances could be of use in the treatment of
PDR[52],althoughtheresultsofpreliminarystudiesseemto
suggestthe exacerbation of diabetic neuropathy asa possible,
not irrelevant, side eﬀect [53].
There are presently just few studies aimed to evaluate
the above-described new drugs in the treatment of diabetic
retinopathy,andtheyareallreferredtopatientswithdiabetic
macular edema.
9. Limits of Anti-VEGF Treatment
A major limit in anti VEGF treatment consists in the evi-
dence that recurrence of retinal neovascularisation following
anti-VEGF treatment is a quite common ﬁnding in a period
t h a tr a n g e sb e t w e e n2w e e k s[ 54] to 3 months [55, 56],
after injection. A reinjection 3-month after the baseline is
probably a reasonable timing in most cases, especially in case
of patients with high-risk PDR. Results in this ﬁeld are still
discrepant between diﬀerent groups. Minnella reported that
the eﬀects of bevacizumab were maintained at 3 months in
15 treated eyes [57].
Conversely, Schmidinger et al. [58] reported that 62% (8
of13)oftreatedeyesrequiredretreatmentwithbevacizumab
3 months after baseline injection because of the appearance
of new vessels.
10. Side Effects of Anti-VEGFTreatment
Along with its therapeutic eﬀect on ocular neovascular-
ization, Bevacizumab treatment may be accompanied by a
number of side eﬀects. Tractional retinal detachment (TRD)
may sometime aﬀect patients with severe PDR [59]t r e a t e d
with this drug. It has been hypothesized that bevacizumab
might induce a ﬁbrotic occlusion of new vessels. The
contraction of this ﬁbrous tissue may, therefore, result in
TRD and vitreous haemorrhage [60–62]. Alternative mech-
anisms underlying the development of TRD could be the
high ﬂuctuations in intraocular pressure (IOP) [63]a n d
deformation of the eye during intravitreal injection with
possible intrusion of the vitreous in the sclera, resulting in
vitreoretinal traction [64]. A possible explanation for the
increased IOP could be the blockage of the internal trabecu-
lae by bevacizumab itself that, being a large 148-kDa protein,
may act as an additional barrier [65].
Lee and Koh [66] documented angiographically a foveal
avascular zone enlargement following pars plana vitrectomy
and treatment with bevacizumab. The authors attributed
this ﬁnding to a total, nonselective blockage of VEGF levels,
when it is well established that physiological concentrations
of VEGF are thought to be essential for maintaining foveal
circulation and visual acuity.
Further studies are needed to verify the systemic side-
eﬀects of anti-VEGF agents, particularly in diabetic subjects
with signiﬁcant vascular complications. Among the systemic
side eﬀects, the most common is hypertension (5.6%),
followed by other cardiovascular complications [67, 68]. The
use of bevacizumab in women of child bearing age need to
be carefully monitored Kumar et al. [69].
At the moment, a large prospective trial aimed to verify
the presence of short- and long-term adverse eﬀects of
bevacizumab treatment is still lacking.
The largest dataset for bevacizumab treatment is pres-
ently represented by a retrospective study [70]o f1 , 1 7 3
patients who received intravitreal bevacizumab and were
followed for 12 months. A number of adverse eﬀect were
reported: seven cases of acute elevation of blood pressure, six
strokes, ﬁve myocardial infarctions, ﬁve deaths, seven cases
of bacterial endophthalmitis, seven cases of tractional retinal
detachment, and four cases of uveitis.
Mason and colleagues retrospectively studied 5,233 in-
travitreal bevacizumab treatments and found a single case
of acute postinjection endophthalmitis [71]. Safety concerns
the use of bevacizumab comes from studies of the intra-
venoususeincancertherapy.Establishedside-eﬀectsinthese
studies include arterial thromboembolism, gastrointestinal
perforation, hemorrhage, hypertensive crisis, and nephrotic6 Experimental Diabetes Research
syndrome [72, 73]. Concerning other anti-VEGF treatments,
the VISION trial performed in patients with neovascular
AMD treated with intravitreal pegaptanib [74, 75]r e p o r t e d
no systemic side eﬀects that could be attributed to treatment
over the course of the study. Some rare speciﬁc ocular com-
plications, such as endophthalmitis, traumatic lens in-
jury, or retinal detachment, were attributed to the injection
procedure rather than to the medication.
The MARINA and ANCHOR studies aimed to treat
neovascular AMD, reported the safety of intravitreal ranibi-
zumab. The MARINA study (two-year observation) showed
no increase in systemic adverse eﬀects with ranibizumab
[76]. By pooling together the safety data from PIER,
MARINA, and ANCHOR (one-year observation) it was
possible to demonstrate an increased rate of vascular events
(2.1% rate of myocardial infarction and stroke) in the rani-
bizumab arms versus the control (1.1%) [77].
Finally, although VEGF has been implicated in the devel-
opment of a number of ocular neovascular diseases, physio-
logic concentrations of endogenous VEGF play a strong role
not only in maintaining the correct perfusion of the retina,
but they also have a key role in the survival of the retinal
neuron, the Muller cell, and photoreceptors [78, 79].
Ar e c e n ts t u d yc o n d u ct e di nm o u s eey e s ,i nf a ct ,r e p o rt e d
a signiﬁcant loss of neuronal retinal ganglions cells due to
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